Erratum: Phase 1 study on docetaxel and ifosfamide in patients with advanced solid tumours (British Journal of Cancer, (1998), 77, 1, (153-158), 10.1038/bjc.1998.24);Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours

British Journal of Cancer

Volumn 77, Issue 1, 1998, Pages 153-158

  Pronk, L C ^a   Schrijvers, D ^b   Schellens, J H M ^a   De Bruijn, E A ^b   Planting, A S Th ^a   Locci Tonelli, D ^c   Groult, V ^c   Verweij, J ^a   Van Oosterom, A T ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c SANOFI   (France)

Author keywords

Docetaxel; Ifosfamide; Phase I study

Indexed keywords

ANTIEMETIC AGENT; DOCETAXEL; GLUCOSE; GRANISETRON; IFOSFAMIDE; ONDANSETRON; POLYSORBATE 80; TROPISETRON;

ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG FORMULATION; DRUG HYPERSENSITIVITY; EDEMA; FEMALE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; MYALGIA; NAIL DISEASE; NAUSEA; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SEPSIS; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING;

EID: 0031964252     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1998.286     Document Type: Erratum

References (39)

1. Aamdal S, Wolff I, Kaplan S, Paridaens R, Kerger R, Schachter J, Wanders J, Franklin H and Verweij J (1994) Taxotere in advanced malignant melanoma: A phase II trials of the EORTC Clinical Trials Group. Eur J Cancer 30A: 1061-1064
2. Aapro MS, Zulian G, Alberto P, Bruno R, Oulid-Aissa D and Le Bail N (1992) Phase I and pharmacokinetic study of RP 56976 in a new ethanol-free formulation of taxotere. Ann Oncol 3 (suppl. 5): 208
3. Bissery MC, Guenard D, Gueritte-Voegelein F and Lavelle F (1991) Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 51: 4845-4852
4. Bisset D, Setanoians A, Cassidy J, Graham MA, Chadwick GA, Wilson P, Auzannet V, Le Bail N, Kaye SB and Kerr DJ (1993) Phase I and pharmacokinetic study of taxotere (RP 56976) administered as a 24-hour infusion. Cancer Res 53: 523-527
5. Ten Bokkel-Huinink WW, Prove AM, Piccart M, Steward W, Tursz T, Wanders J, Franklin H, Clavel M, Verweij J, Alakl M, Bayssas M and Kaye SB (1994) A phase II trial with docetaxel (taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group. Ann Oncol 5: 527-532
6. Brundage MD, Pater JL and Zee B (1993) Assessing the reliability of two toxicity scales: implications for interpretating toxicity data. J Natl Cancer Inst 85: 1138-1148
7. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, Fields S, Weiss G, Eckardt J, Rodriguez G, Rinaldi D, Wall J, Cook G, Smith S, Vreeland F, Bayssas M, Le Bail N and Von Hoff D (1993) Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion every 3 weeks. J Clin Oncol 11: 950-958
8. Catimel G, Verweij J, Mattijsen V, Hanauske A, Piccart M, Wanders J, Franklin H, Le Bail N, Clavel M and Kaye SB (1994) Docetaxel (taxotere): an active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 5: 533-537
9. Cerny T, Kaplan S, Pavlidis N, Schöffski P, Epelbaum R, Van Meerheek J, Wanders J, Franklin HR and Kaye S, for the ECTG (1994) Docetaxel (taxotere) is active in non-small cell lung cancer: A phase II trial of the EORTC-Clinical Trials Group. Br J Cancer 70: 384-387
10. Chevallier B, Fumoleau P, Kerbrat P, Dieras V, Roche H, Krakowski I, Azli N, Bayssas M, Lentz MA and Van Glabbeke M (1995) Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 13: 314-322
11. Denis JN, Greene AE, Guenard D, Gueritte-Voegelein F, Mangatal L and Potier PA (1988) A highly efficient practical approach to natural taxol. J Am Chem Soc 110: 5917-5919
12. Ettinger DS. (1989). Ifosfamide in the treatment of non-small cell lung cancer. Semin Oncol 16 (suppl. 5): 31-38
13. Extra JM, Rousseau F, Bruno R, Clavel M, Le Bail N, Marty M (1993) Phase I and pharmacokinetic study of taxotere (RP56976: NSC 628503) given as a short intravenous infusion. Cancer Res 53: 1037-1042
14. De Forni M, Rougier P, Adenis A, Ducreux M, Djazouli K, Adams D, Clouet P, Blanc C, Bayssas M, Bonneterre J and Armand JP (1994) Phase II study of taxotere in locally advanced and/or metastatic pancreatic cancer. Ann Oncol 5 (suppl. 5): 509
15. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Ki Hong W and Raber M (1995) Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small cell lung cancer. J Clin Oncol 13: 645-651
16. Gueritte-Voegelein F, Guenard D, Lavelle F, Le Goff MT, Mangatal L and Potier P (1991) Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 34: 992-998
17. Harrison S, Dykes D, Sheperd RV, Griswold DP and Bissery MC (1992) Response of human tumor xenografts to taxotere. Proc Am Assoc Cancer Res 33: 526
18. Hilkens PHE, Verweij J, Stoter G, Vecht CHJ, Van Putten WLJ and VD Bent MJ (1996) Peripheral neurotoxicity induced by docetaxel. Neurology 46: 104-108
19. Hilkens PHE, Pronk LC, Verweij J, Vecht CHJ, Van Putten WLJ and VD Bent MJ (1997) Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 75: 417-422
20. Van Hoesel QGCM, Verweij J, Catimel G, Clavel M, Kerbrat P, Van Oosterom AT, Kerger J, Tursz T, Van Glabbeke M, Van Pottelsberghe C, Le Bail N and Mouridsen H, for the EORTC Soft Tissue and Bone Sarcoma Group (1994) Phase II study with docetaxel (taxotere) in advanced soft tissue sarcomas of the adult. Ann Oncol 5: 539-542
21. Hoffmann W, Weidmann B, Migeod F, Könner J and Seeber S (1990) Epirubicin and Ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. Cancer Chemother Pharmacol 26 (suppl): 69-70
22. Kaye SB, Mead GM, Fossa S, Cullen M, De Wit R, Bodrogi I, Van Groeningen C, Sylvester R, Stenning S, Vermeylen K, Lallemand E and De Mulder P. From the MRC and EORTC Data Centres, Cambridge and Brussels (1995) An MRC/EORTC randomised trial in poor prognosis metastatic teratoma, comparing BEP with BOP-VIP. Proc ASCO, 14: 246
23. 2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75: 968-972
24. Nicoletti MI, Massazza G, Abbott BJ, D'Incalci M and Giavazzi R (1992) Taxol and taxotere antitumor activity on human ovarian carcinoma xenografts. Proc Ant Assoc Cancer Res 33: 519
25. Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D, Jaiyesimi I, Vreeland F, Bayssas MMG and Raber MN (1992) Phase I trial of taxotere: five day schedule. J Natl Cancer Inst 84: 1781-1788
26. Piccart MJ, Klijn J, Mauriac L, Nooij M, Paridaens R, Coleman R, Selleslags J, Van Vreckem A and Van Glabbeke M (1994) Weekly docetaxel with or without prophylactic steroids as 2nd line treatment for metastatic breast cancer: a randomized trial of the EORTC Breast Cancer Study Group. Ann Oncol 5 (suppl 8): 27
27. Pinedo HM and Verweij J (1986) The treatment of soft tissue sarcomas with focus on chemotherapy. A review Radiother Oncol 5: 193-205
28. Pronk LC, Stoter G and Verweij J (1995) Docetaxel (Taxotere): single agent activity, development of combination treatment and reducing side effects. Cancer Treatment Rev 21: 463-478
29. Pronk LC, Schellens JHM, Planting ASTH, VD Bent MJ, VD Burg Mel, De Boer-Dennert M, Ma J, Blanc C, Harteveld M, Bruno R, Stoter G and Verweij J (1997) A phase I and pharmacological study of docetaxel and cisplatin in patients with advanced solid tumors. J Clin Oncol 15: 1071-1079
30. Ringel I and Horwitz SB (1991) Studies with RP 56976 (taxotere): a semi-synthetic analog of taxol. J Natl Cancer Inst 83: 288-291
31. Rowinsky EK and Donchower RC (1991) The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmac Ther 52: 35-84
32. Rowinsky EK, Gilbert MR, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Clark B, Sartorius SE, Cornblath DR, Hendricks CB and Donehower RC (1991) Sequences of taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9: 1692-1703
33. Schrijvers D, Wanders J, Dirix L, Prove A, Vonck I, Van Oosterom A and Kaye S (1993) Coping with toxicities of docetaxel (Taxotere). Ann Oncol 4: 610-611
34. Seidman AD, Hudis C, Crown JPA, Balmaceda C, Lebwohl D, Currie V, Gilewski T, Hakes T, Robles M, Klent K, Lepore J and Norton L (1993) Phase II evaluation of taxotere as initial chemotherapy for metastatic breast cancer. Proc ASCO 12: 63
35. Sulkes A, Smyth J, Sessa C, Van Oosterom AT, Vermorken J, Kaye SB, Le Bail N and Verweij J for the EORTC Early Clinical Studies Group (1991) Docetaxel (taxotere) in advanced gastric cancer: results of a phase II clinical trial. Br J Cancer 70: 380-383
36. Tomiak E, Piccart MJ, Kerger J, Lips S, Awada A, De Valeriola D, Ravoet C, Lossignol D, Sculier JP, Auzannet V, Le Bail N, Bayssas M and Klavtersky J (1993) Phase I study of taxotere (RP 56976, NSC 628503) administered as a one hour intravenous infusion on a weekly basis. J Clin Oncol 12: 1458-1467
37. Trudeau M, Eisenhauer E, Lofters W, Norris B, Muldal A, Letendre F, Vandenburg T and Verma S (1993) Phase II study of taxotere as first line chemotherapy for metastatic breast cancer: A National Cancer Institute of Canada. Clinical Trial Group study. Proc ASCO 12: 64
38. Valero V, Esparza L, Holmes F, Walters R, Fraschini G, Theriault R, Dhingra K, Buzdar A, Bellet R, Slattery A, Pazdur R, Raber M, Bayssas M and Hortobagyi G (1993) Phase II study of taxotere in refractory metastatic breast cancer. Proc ASCO 12: 96
39. WHO handbook for reporting results of cancer treatment Geneva. WHO Offset Publication 1979 48: pp. 22-26